Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 17/20 | 0.73 |
| ▸ | MKNK2 | Q9HBH9 | 17/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | EIF4E | P06730 | 1/20 | 0.67 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15288200 | 0.97 | MKNK1 (0.76) | MKNK1MKNK2CYP3A4EIF4EEGLN2 | |
| SCHEMBL15288603 | 0.90 | MKNK1 (0.66) | MKNK1MKNK2CYP3A4EIF4EEGLN2 | |
| SCHEMBL15286214 | 0.90 | MKNK1 (0.66) | MKNK1MKNK2CYP3A4EIF4EEGLN2 | |
| SCHEMBL15286278 | 0.88 | MKNK1 (0.66) | MKNK1MKNK2CYP3A4EIF4EEGLN2 | |
| SCHEMBL15288441 | 0.87 | MKNK1 (0.93) | MKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL15286120 | 0.86 | MKNK1 (0.60) | MKNK1MKNK2CYP3A4EIF4EEGLN2 | |
| SCHEMBL15288836 | 0.86 | MKNK1 (0.62) | MKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL15286459 | 0.84 | MKNK1 (1.00) | MKNK1MKNK2CYP3A4EIF4E | |
| SCHEMBL15288573 | 0.84 | MKNK1 (0.57) | MKNK1MKNK2CYP3A4EIF4EEGLN2 | |
| SCHEMBL16304121 | 0.84 | MKNK1 (0.55) | MKNK1MKNK2CYP3A4EIF4EEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-22 | — | — | US | disclosed |
| US-20190315755-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2019-10-17 | — | — | US | disclosed |
| US-20190211020-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-07-11 | — | — | US | disclosed |
| US-10280168-B2 | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-05-07 | — | — | US | disclosed |
| US-20180208600-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-26 | — | — | US | disclosed |
| EP-3321268-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2018-05-16 | — | — | EP | disclosed |
| US-9908886-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-06 | — | — | US | disclosed |
| EP-2831079-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2017-08-16 | — | — | EP | disclosed |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-02-05 | — | — | US | disclosed |
| EP-2831079-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2015-02-04 | — | — | EP | disclosed |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-18 | — | — | US | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280168-B2 | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof | MAPKAPK2, NEK2, MKNK2 | MKNK1 6/4885MKNK2 3/4885CYP3A4 3528/4885 |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | MKNK1 6/4885MKNK2 3/4885CYP3A4 3519/4885 |
| US-20190315755-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | MKNK1 4/4885MKNK2 2/4885CYP3A4 4082/4885 |
| US-20190211020-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | MKNK1 6/4885MKNK2 3/4885CYP3A4 3519/4885 |
| US-20180208600-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | MKNK1 4/4885MKNK2 2/4885CYP3A4 4082/4885 |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | MKNK2, MKNK1, MAPKAPK2 | MKNK1 2/4885MKNK2 1/4885CYP3A4 4317/4885 |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | MKNK1 4/4885MKNK2 2/4885CYP3A4 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.